US2182786A
(en)
|
1938-09-14 |
1939-12-12 |
Dow Chemical Co |
Hydroxy-alkyl ethers of benzophenone
|
US2831768A
(en)
|
1956-01-19 |
1958-04-22 |
Eastman Kodak Co |
Polymeric light-sensitive photographic elements
|
US4117121A
(en)
|
1977-04-22 |
1978-09-26 |
Hoffmann-La Roche Inc. |
Method of increasing bile flow and decreasing lipid levels
|
CS196471B1
(cs)
|
1977-11-28 |
1980-03-31 |
Ivan Lukac |
Nové p-acylované fenoxyetanoly
|
US4656187A
(en)
|
1981-08-03 |
1987-04-07 |
Eli Lilly And Company |
Treatment of mammary cancer
|
EP0072475B1
(de)
|
1981-08-17 |
1986-08-20 |
F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft |
Carbaminsäureester, Verfahren zu deren Herstellung, Schädlingsbekämpfungsmittel, die diese Verbindungen als Wirkstoffe enthalten, sowie Verwendung solcher Verbindungen und Mittel zur Bekämpfung von Schädlingen
|
FI77839C
(fi)
|
1982-05-27 |
1989-05-10 |
Farmos Oy |
Foerfarande foer framstaellning av nya terapeutiskt effektiva trifenylalkan- och alkenderivat.
|
GB2126576B
(en)
|
1982-06-25 |
1985-06-19 |
Farmos Group Limited |
Alkane and alkene derivatives
|
US5491173A
(en)
|
1982-06-25 |
1996-02-13 |
Orion-Yhtyma Oy |
Tri-phenyl alkene derivatives and their preparation and use
|
US4625048A
(en)
|
1982-08-13 |
1986-11-25 |
Hoffmann-La Roche Inc. |
Carbamic acid esters
|
US4729999A
(en)
|
1984-10-12 |
1988-03-08 |
Bcm Technologies |
Antiestrogen therapy for symptoms of estrogen deficiency
|
US4935243A
(en)
|
1988-12-19 |
1990-06-19 |
Pharmacaps, Inc. |
Chewable, edible soft gelatin capsule
|
DE3936592A1
(de)
|
1989-11-03 |
1991-05-08 |
Basf Ag |
Verfahren zur herstellung und reinigung von 2-hydroxy-4-(2'-hydroxy-ethoxy)phenylarylketonen
|
US5189212A
(en)
|
1990-09-07 |
1993-02-23 |
University Of Georgia Research Foundation, Inc. |
Triarylethylene carboxylic acids with estrogenic activity
|
CA2092996A1
(en)
|
1990-10-01 |
1992-04-02 |
David Yang |
High affinity tamoxifen derivatives and uses thereof
|
US6096874A
(en)
|
1990-10-01 |
2000-08-01 |
Board Of Regents, The University Of Texas System |
High affinity tamoxifen derivatives
|
US5219548A
(en)
|
1990-10-01 |
1993-06-15 |
Board Of Regents, The University Of Texas System |
High affinity halogenated-tamoxifen derivatives and uses thereof
|
US5118667A
(en)
|
1991-05-03 |
1992-06-02 |
Celtrix Pharmaceuticals, Inc. |
Bone growth factors and inhibitors of bone resorption for promoting bone formation
|
US5196435A
(en)
|
1991-11-21 |
1993-03-23 |
Eli Lilly And Company |
Melatonin derivatives and combinations with antiestrogen compounds for treating mammalian breast carcinoma
|
GB9207437D0
(en)
|
1992-04-03 |
1992-05-20 |
Orion Yhtymae Oy |
Topical administration of toremifene and its metabolites
|
US5352699A
(en)
|
1992-04-30 |
1994-10-04 |
University Of Massachusetts Medical Center |
Use of retinioc acid to treat vaginal atrophy
|
US5446203A
(en)
|
1992-08-25 |
1995-08-29 |
New York University |
Synthesis of haloenones and aryl or alkyl substituted enones or alkenes
|
DE4335876A1
(de)
|
1993-10-17 |
1995-04-20 |
Schering Ag |
Kombination von Progesteronantagonisten und Antiöstrogenen mit partialer agonistischer Wirkung für die Hormonsubstitutions-Therapie für peri- und postmenopausale Frauen
|
US5461064A
(en)
|
1993-12-21 |
1995-10-24 |
Eli Lilly And Company |
Methods of inhibiting atrophy of the skin and vagina
|
US5650425A
(en)
|
1994-04-04 |
1997-07-22 |
Pharmos Corporation |
Permanently ionic derivatives of steroid hormones and their antagonists
|
US5681835A
(en)
|
1994-04-25 |
1997-10-28 |
Glaxo Wellcome Inc. |
Non-steroidal ligands for the estrogen receptor
|
US5604248A
(en)
|
1994-05-05 |
1997-02-18 |
Eli Lilly And Company |
Method for minimizing the uterotrophic effect of tamoxifen and tamoxifen analogs
|
US5470883A
(en)
|
1994-05-23 |
1995-11-28 |
Stromberg; Brent V. |
Method of treating peripheral vasoconstriction with tamoxifen citrate
|
FI100692B
(fi)
|
1994-05-24 |
1998-02-13 |
Leiras Oy |
Menetelmä farmaseuttisten koostumusten valmistamiseksi, jolloin koostu mukset pohjautuvat mikroemulsiogeeleihin sekä uusia mikroemulsioihin p ohjautuvia geelejä
|
US5441986A
(en)
|
1994-07-19 |
1995-08-15 |
Pfizer Inc. |
Estrogen agonists as remedies for prostate and cardiovascular diseases
|
GB9418067D0
(en)
*
|
1994-09-07 |
1994-10-26 |
Orion Yhtymae Oy |
Triphenylethylenes for the prevention and treatment of osteoporosis
|
US5658931A
(en)
|
1994-09-20 |
1997-08-19 |
Eli Lilly And Company |
Method for inhibiting mammalian breast carcinoma with tamoxifen, and analogs thereof, and certain naphthyl compounds
|
US6562862B1
(en)
|
1994-10-20 |
2003-05-13 |
Eli Lilly And Company |
Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
|
CA2206422A1
(en)
|
1994-11-29 |
1996-06-06 |
Hoechst Marion Roussel, Inc. |
Method of using triaryl-ethylene derivatives in the treatment and prevention of osteoporosis
|
US5821254A
(en)
|
1995-02-17 |
1998-10-13 |
The United States Of America As Represented By The Department Of Health And Human Services |
Uses of 9-cis-retinoic acids and derivatives thereof alone or in combination with antineoplastic agents in the prevention or treatment of cancer
|
GB9509572D0
(en)
|
1995-05-11 |
1995-07-05 |
Cancer Res Campaign Tech |
Cancer therapy
|
DE19526146A1
(de)
|
1995-07-07 |
1997-01-09 |
Schering Ag |
Triphenylethylene, Verfahren zu deren Herstellung, diese Triphenylethylene enthaltene pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
|
US5747059A
(en)
|
1996-01-11 |
1998-05-05 |
Novo Nordisk A/S |
Atrophy of skin/mucous membrane
|
GB9604577D0
(en)
|
1996-03-04 |
1996-05-01 |
Orion Yhtymae Oy |
Serum cholesterol lowering agent
|
DE19653736C2
(de)
|
1996-12-12 |
2002-11-21 |
Lancaster Group Gmbh |
Kosmetisches Präparat mit Peptidzusatz
|
GB9803521D0
(en)
|
1998-02-19 |
1998-04-15 |
Orion Yhtymo Oy |
New compounds and pharmaceutical compositions thereof
|
US6632447B1
(en)
|
1998-05-07 |
2003-10-14 |
The University Of Tennessee Research Corporation |
Method for chemoprevention of prostate cancer
|
US6465445B1
(en)
|
1998-06-11 |
2002-10-15 |
Endorecherche, Inc. |
Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
|
US6525084B2
(en)
|
1998-07-23 |
2003-02-25 |
Novo Nordisk A/S |
Stable pharmaceutical formulation
|
US6245352B1
(en)
|
1999-04-27 |
2001-06-12 |
Eli Lilly And Company |
Pharmaceutical formulation
|
TW593256B
(en)
|
1999-11-16 |
2004-06-21 |
Hormos Medical Oy Ltd |
Triphenylalkene derivatives and their use as selective estrogen receptor modulators
|
CO5271697A1
(es)
|
2000-01-12 |
2003-04-30 |
Pfizer Prod Inc |
Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona
|
PL357163A1
(en)
|
2000-01-28 |
2004-07-26 |
Endorecherche, Inc. |
Selective estrogen receptor modulators in combination with estrogens
|
AU775089B2
(en)
|
2000-02-17 |
2004-07-15 |
Appleton Papers Inc. |
Process for preparing alkoxy or arylmethoxy aroxyethanes
|
US20010034340A1
(en)
|
2000-03-20 |
2001-10-25 |
American Home Products Corporation |
Hormone replacement therapy
|
US6245819B1
(en)
|
2000-07-21 |
2001-06-12 |
Hormos Medical Oy, Ltd. |
Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause
|
FI111710B
(fi)
|
2001-05-04 |
2003-09-15 |
Hormos Medical Oy Ltd |
Menetelmä terapeuttisesti aktiivisen yhdisteen valmistamiseksi
|
DE60239207D1
(de)
|
2001-08-10 |
2011-03-31 |
Takeda Pharmaceutical |
Gnrh-agonistische kombinationsmittel
|
US20070197664A1
(en)
|
2001-11-29 |
2007-08-23 |
Steiner Mitchell S |
Prevention and treatment of androgen-deprivation induced osteoporosis
|
EP1574212A1
(en)
|
2001-11-29 |
2005-09-14 |
GTX Inc. |
Prevention and treatment of androgen-deprivation induced hot flashes, decreased lean muscle mass, loss of libido or erectile dysfunction
|
WO2003103649A1
(en)
|
2002-06-06 |
2003-12-18 |
Hormos Medical Corporation |
Method for the inhibition of atrophy or for treatment or prevention of atrophy-related symptoms in women
|
US20040248989A1
(en)
|
2003-06-05 |
2004-12-09 |
Risto Santti |
Method for the treatment or prevention of lower urinary tract symptoms
|
US8236861B2
(en)
|
2004-02-13 |
2012-08-07 |
Hormos Medical Corporation |
Method for enhancing the bioavailablity of ospemifene
|
US20050187302A1
(en)
|
2004-02-23 |
2005-08-25 |
Hormos Medical Corporation |
Method for treatment or prevention of osteoporosis in individuals with high bone turnover
|
US8642079B2
(en)
|
2004-02-23 |
2014-02-04 |
Hormos Medical Corporation |
Solid formulations of ospemifene
|
US7405303B2
(en)
|
2004-02-25 |
2008-07-29 |
Smithkline Beecham Corporation |
Substituted quinoline compounds for use as selective estrogen receptor modulator
|
US8758821B2
(en)
|
2004-05-04 |
2014-06-24 |
Hormos Medical Ltd. |
Oral formulations of ospemifene
|
US7504530B2
(en)
|
2007-02-14 |
2009-03-17 |
Hormos Medical Ltd. |
Methods for the preparation of fispemifene from ospemifene
|
SI2121553T1
(sl)
*
|
2007-02-14 |
2012-11-30 |
Hormos Medical Ltd |
Postopek za pripravo terapevtsko uporabnih trifenilbutenskih derivatov
|
EP2526080B1
(en)
|
2010-01-19 |
2014-03-26 |
Cambrex Karlskoga AB |
New processes for producing benzophenone derivatives
|